title: Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.
abstract: Oralair(®) (OA) (Stallergenes, Antony, France) is a unique pre- and co-seasonal 5-grass-pollen sublingual immunotherapy tablet launched in 2008, and now approved in 31 countries worldwide for the treatment of grass-pollen allergic rhinitis and rhinoconjunctivitis. OA is the first oral treatment with a consistent, well-balanced allergen extract that mimics natural exposure and sensitization. A wealth of data exists from over 5 years of clinical and real-world experience demonstrating the efficacy and safety of OA for grass-pollen-allergy treatment. OA is highly effective from the first pollen season in all patient subgroups, including children and those with comorbid mild asthma, irrespective of sensitization status and symptom severity. OA also has sustained long-term benefits for symptom control and quality of life. This article provides an overview of the pharmacodynamics and pharmacology of OA; its efficacy, safety, tolerability and cost-effectiveness for the treatment of allergic rhinitis and rhinoconjunctivitis and its role in clinical practice.
authors.affiliation: Department of Respiratory Diseases, Rangueil-Larrey Hospital, 24 Chemin de Pouvourville - TSA 30030, 31059 Toulouse Cedex 9, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Didier
authors.forename: Ulrich
authors.initials: U
authors.lastname: Wahn
authors.forename: Friedrich
authors.initials: F
authors.lastname: Horak
authors.forename: Linda S
authors.initials: LS
authors.lastname: Cox
mesh_terms: D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage; D006801:Humans; D006109:Poaceae; D011058:Pollen; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*; D063729:Sublingual Immunotherapy / Q000379:methods*; D013607:Tablets
chemical_list: D000485:Allergens; D013607:Tablets
keywords: 5-grass-pollen tablet; allergen-specific immunotherapy; allergic rhinitis; allergic rhinoconjunctivitis; clinical trial; efficacy; pollinosis; safety; sublingual immunotherapy